February 14, 2017 / 10:30 PM / 6 months ago

BRIEF-Merck announces Epoch study of Verubecestat

Feb 14 (Reuters) - Merck & Co Inc :

* Merck announces epoch study of verubecestat for the treatment of people with mild to moderate alzheimer's disease to stop for lack of efficacy

* Merck & Co Inc - apecs study in people with prodromal alzheimer's disease to continue

* Merck & Co Inc - results from protocol 019 are expected in February 2019.

* Merck & Co Inc - Merck is stopping epoch study following recommendation of external data monitoring committee

* Merck & Co Inc says edmc noted that safety signals observed in study "are not sufficient to warrant stopping study 017"

* Merck - external data monitoring committee determined that there was "virtually no chance" of finding positive clinical effect in epoch study

* Merck & Co Inc says edmc recommended that protocol 019, also known as apecs, continue unchanged

* Merck & Co Inc - while co is "disappointed" that a benefit was not observed in epoch study, co's work continues with apecs Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below